Senti Bio reports FY2022 net loss of $58.2M; cash runway through Q1 2024; IND on track for H2 2023

Senti Biosciences, Inc.

Cash, cash equivalents & short-term investments of $98.6M as of Dec 31, 2022; expect funding through at least Q1 2024.
FY2022 net loss $58.2M ($2.23 per share) vs $55.3M ($19.00 per share) in 2021; R&D expenses $34.1M, G&A $40.8M.
SENTI-202 IND application for AML/MDS planned in H2 2023; preclinical data to be presented at AACR April 2023.
Capital expenditures of $8.5M in Q4 2022 driven by cGMP manufacturing facility buildout and equipment.
Collaborations with Spark Therapeutics and BlueRock Therapeutics advancing Gene Circuit programs.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Senti Biosciences, Inc. reported the year ended December 31, 2022 results: net income Net loss ... $58.2 million, EPS $2.23 per share.

Period: the year ended December 31, 2022
Net income: Net loss ... $58.2 million
EPS: $2.23 per share
Result: reported results

Exact text from the filing

Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-23-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.